Research Article
Preemptive Treatment of Nausea and Vomiting of Pregnancy: Results of a Randomized Controlled Trial
Table 4
Comparison of effectiveness between the two arms.
| | | Preemptive () | Controls () | |
| | Rates (%) of PUQE ≥ 11 in first 3 weeks of NVP | 4 (15.4%) () | 9 (39.13%) () | | | AUC of PUQE × Time in 1st trimester (SD) | 6.38 (1.58) () | 6.11 (2.24) () | NS | | NVP resolved before labor | 18/23 (78.2%) | 11/22 (50%) | <0.002 | | Gest. age when NVP resolved (median wk) | 26 | 33 | 0.18 | | Distribution of HG in previous versus this pregnancy* | | | | | HG in previous pregnancy | 19 | 11 | 0.047* | | HG in present pregnancy | 6 | 6 | | | Mean daily dose of Diclectin {mg/kg (SD)} | 0.65 (0.23) | 0.56 (0.24) | 0.2 | Mean gestational age (in weeks)
when NVP symptoms began (SD) | 5.30 (1.02) | 5.45 (1.88) | | | Mean start of preemptive therapy (SD) | 3.8 (0.98) | | |
|
|
AUC = Area under the curve.
|
